scispace - formally typeset
H

Hengquan Wan

Researcher at University of South China

Publications -  6
Citations -  41

Hengquan Wan is an academic researcher from University of South China. The author has contributed to research in topics: Piwi-interacting RNA & Medicine. The author has an hindex of 1, co-authored 3 publications receiving 5 citations.

Papers
More filters
Journal ArticleDOI

Role of PIWI-interacting RNAs on cell survival: Proliferation, apoptosis, and cycle

TL;DR: This review summarizes the research progress regarding the roles of piRNAs in the cell proliferation, apoptosis, and cycle and indicates the mechanism ofPiRNAs is unclear.
Journal ArticleDOI

PIWI-interacting RNAs and PIWI proteins in diabetes and cardiovascular disease: Molecular pathogenesis and role as biomarkers.

TL;DR: In this paper, the authors summarize recent evidence and evaluate the molecular mechanism of the involvement of piRNAs and PIWI proteins in CVD, and conclude that PIRNAs are associated with some molecular and cellular pathways.
Journal ArticleDOI

CircRNAs in diabetic cardiomyopathy.

TL;DR: In this article, the authors summarized recent studies on the role of circRNAs in the pathophysiological process to provide novel prevention and treatment strategies for diabetic cardiomyopathy, oxidative stress, inflammation, endothelial dysfunction, myocardial fibrosis and cell death.
Journal ArticleDOI

MicroRNA-223-3p promotes pyroptosis of cardiomyocyte and release of inflammasome factors via downregulating the expression level of SPI1 (PU.1).

TL;DR: Wang et al. as discussed by the authors showed that miR-223-3p was significantly increased in cardiomyocytes induced by high glucose, whereas the down-regulation of miR223 3p weakened it.
Journal ArticleDOI

Farnesoid X Receptor Deficiency Induces Hepatic Lipid and Glucose Metabolism Disorder via Regulation of Pyruvate Dehydrogenase Kinase 4

TL;DR: Results identify FXR as a nuclear transcription factor that regulates glucose and lipid metabolism balance through PDK4, providing further insights into the mechanism of FXR agonists in the treatment of metabolic diseases.